With classical ADC therapies demonstrating sustained clinical success and reshaping the standard of oncology care, eyes are turning towards up-and-coming novel conjugate with non-cytotoxic payloads and novel targeting moieties compared to tried and tested ADCs. 

Don’t miss this session delving into the challenges and opportunities of novel cytotoxic payloads, AOCs, DACs, ISACs and beyond.